Prelude Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Prelude Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,360	Closed	-$857K	–	2326
2019 Q4	$857K	Buy	7,360 +3,116	+73%	+$361K	0.03%	433
2019 Q3	$486K	Buy	+4,244	New	+$422K	0.02%	526
2017 Q4	–	Sell	-500	Closed	-$46K	–	1972
2017 Q3	$46K	Buy	+500	New	+$48K	﹤0.01%	1129
2016 Q4	–	Sell	-4,300	Closed	-$535K	–	1957
2016 Q3	$535K	Buy	+4,300	New	+$508K	0.06%	299
2016 Q2	–	Sell	-2,000	Closed	-$229K	–	1860
2016 Q1	$229K	Buy	+2,000	New	+$235K	0.03%	509
2015 Q2	–	Sell	-677	Closed	-$65K	–	2266
2015 Q1	$65K	Sell	677 -332	-33%	-$24.8K	0.01%	1187
2014 Q4	$68K	Buy	1,009 +9	+0.9%	+$558	0.01%	1159
2014 Q3	$54K	Buy	1,000 +700	+233%	+$34.5K	0.01%	1374
2014 Q2	$13K	Sell	300 -2,216	-88%	-$90.5K	﹤0.01%	1795
2014 Q1	$87K	Buy	+2,516	New	+$80.1K	0.01%	1072

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

SGCM

Sand Grove Capital Management London, United Kingdom $444M AUM 131.11% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Prelude Capital Management's CBPO Position: Q1 2020 in Review

Prelude Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2020, closing a stake of 7,360 shares — an estimated $857K sold.

Prelude Capital Management first reported a position in CBPO in Q1 2014 and held it in 10 quarters. The position peaked at $857K in Q4 2019. 84 funds tracked by Wall St. Rank hold CBPO as of Q1 2020.

Prelude Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 7,360 China Biologic Products Holdings, Inc. shares in Q1 2020, an estimated $857K.
Prelude Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q1 2014 and held it in 10 quarters.
Prelude Capital Management's China Biologic Products Holdings, Inc. position peaked at $857K in Q4 2019.
84 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.